United Therapeutics Corporation (UTHR)

240,73 +0,73 (+0,30%) Alla chiusura: 04:00PM EST

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 985

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	5,32M	56,15M	1955
Mr. Michael I. Benkowitz	President & COO	2,83M	7,83M	1972
Mr. James C. Edgemond	CFO & Treasurer	2,01M	1,49M	1968
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary	2,31M	13,2M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	N/D	N/D	N/D
Ms. Holly Hobson	Associate Vice President of Human Resources	N/D	N/D	N/D
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics	N/D	N/D	N/D
Mr. Patrick Poisson	Executive VP of Technical Operations	N/D	N/D	1968
Dr. Leigh Peterson	Senior Vice President of Product Development	N/D	N/D	N/D
Mr. Gil Golden	Senior VP & Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Governance aziendale

L'ISS Governance QualityScore di United Therapeutics Corporation al 1 dicembre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 5; diritti degli azionisti: 3; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.